Israel Medica2010 Companies Catalogue - Israeli-South African ...

BSP Biological Signal Processing Ltd.
Back to TOC
Company at a Glance
www.bspmedical.com
Founded in 2000, BSP Biological Signal Processing Ltd. is a medical device company with corporate offices
in Tel Aviv, Israel and a US subsidiary – BSP, Inc. – with sales and marketing offices in Rockville Maryland, US.
BSP is publicly traded on the Tel Aviv Stock Exchange since 2006 (TASE:BSP).
BSP develops and commercializes a new generation of systems for non invasive diagnosis and monitoring of
Ischemic Heart Disease (IHD), based on advanced signal processing of the ECG signal which integrates the
Company’s unique, patented, HyperQ technology.
Category, Subcategory & Therapeutic Area(s)
Category:
Subcategory:
Therapeutic Area(s):
Company Status:
Medical Devices
Diagnostics
Cardiovascular
Initial Revenues
Technology & Product(s)
BSP has pioneered the clinical implementation of high-frequency ECG and has developed it into a fast,
accurate, low-cost, simple to operate and non-radiating technology for detecting IHD with greater clinical
value than the current standard ECG. The company’s proprietary HyperQ technology extracts and analyses
the high-frequency components of the ECG and provides a unique diagnostic index. Thousands of patients
have been tested with the HyperQ system to date, demonstrating consistently that HyperQ is far superior to
conventional ECG both in sensitivity and specificity, with the potential to save up to 50% of the unnecessary
radioactive imaging procedures, while improving the standard of care. BSP’s intellectual property portfolio is
backed by four granted patents and 14 filed applications in different stages.
HyperQ EX-300 Stress System: The HyperQ EX-300 Stress system enables an accurate and risk-free
procedure for the early diagnosis of Ischemic Heart Disease (IHD). HyperQ stress testing is performed in a
similar manner to a standard clinical stress test, providing the conventional stress ECG results, and the
HyperQ test results, with extraordinary clinical accuracy. The system is offered as a combination of software
and hardware that connects to a treadmill or stationary bicycle and constitutes a full ergometry (stress ECG)
station that is FDA (510k) cleared and CE certified.
Goal
Objectives: The company’s primary strategic objectives include establishing HyperQ as the first line modality
for monitoring and diagnosis of Ischemic Heart Disease in cardiology clinics, ambulatory and hospital
settings, and attaining reimbursement code and premium coverage over competitors for the HyperQ
diagnostic modality in the US. Growth in market penetration and market share will be achieved through a
combination of business partnerships with equipment and healthcare service providers, and by the
establishment of a global marketing and sales presence.
Target Businesses: Distributors specializing in cardiovascular diagnostic devices, leading
manufacturers in the field of cardiovascular diagnostic devices for potential business partnerships, leading
health service providers.
Target Countries:
Worldwide
14